Haemonetics (HAE) Share-based Compensation (2009 - 2026)

Haemonetics has reported Share-based Compensation for 18 years, with the latest figure at $9.1 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 31.57% year-over-year to $9.1 million; the trailing twelve-month figure through Mar 2026 stood at $33.8 million (up 14.14% YoY), and the FY2026 full-year result was $33.8 million, up 14.14% from the prior year.
• Share-based Compensation for Q1 2026 stood at $9.1 million, up from $7.8 million in the prior quarter.
• The five-year high for Share-based Compensation was $9.3 million in Q2 2025, with the low at $5.1 million in Q2 2022.
• Average Share-based Compensation over 5 years is $7.2 million, with a median of $7.1 million recorded in 2023.
• Year-over-year, Share-based Compensation slipped 28.31% in 2022 and jumped 38.47% in 2023.
• Tracing HAE's Share-based Compensation over 5 years: stood at $7.5 million in 2022, then declined by 3.66% to $7.2 million in 2023, then grew by 13.81% to $8.2 million in 2024, then retreated by 5.05% to $7.8 million in 2025, then grew by 17.03% to $9.1 million in 2026.
• The last three Share-based Compensation figures came in at $9.1 million (Q1 2026), $7.8 million (Q4 2025), and $7.6 million (Q3 2025), per Business Quant data.

Peer Comparison